CNBC World

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

This is a short WorldPing brief. The full report was published by CNBC World.

Read the full report at CNBC World

More coverage: all world news on WorldPing.

Related news

Fourteen men go on trial in Paris over deadliest small-boat Channel crossingWorldPing
The Guardian

Fourteen men go on trial in Paris over deadliest small-boat Channel crossing

Sinking of inflatable dinghy in 2021 resulted in 31 people dead or missing, including a seven-year-old child Fourteen men will go on trial in Paris on Tuesday over the deaths of at least 31 people in the worst mass drowning from a small-boat crossing…

Brief by WorldPing · Original reporting by The Guardian